- Lesson From Dubai: Start Cutting Risk In Your Portfolio
- Iranian Seizure of British Yacht Pushes Oil Above $77
- Should Homeowners Be Able to Stop Paying Mortgage?
- Buffett's Predictions For Next Year—And Every Year
- The World's Biggest Debtor Nations
- Goldman Sachs Party Ban: No Gatherings of 12 or More
- Fed Tweaking Plan to Pull Money Back out of Economy
- Scientists Gone Wild: Climate Debate Turns Nasty
- Blue Nile CEO: Having 'Best Cyber Monday Ever'
- Hershey Shares: What Options Are Saying
- Nov. 30: Unusual Volume Leaders
- Why Careful Shoppers Are Great for the Box Office
- Blue Nile CEO: 'We're Having the Best Cyber Monday Ever'
- Best Online Retailers to Buy Now: Internet Analyst
- ESPN The Magazine’s Body Issue: A Financial Success
- Cyber Monday: The Last Vestige of Dotcom Hype
- Dubai Fear is 'Noise'—Stay Fully Invested: Strategist
- Tech Comes to Holiday Shopping's Rescue?
MOST SHARED
- Timeless and Time-Tested Warren Buffett Watch Predictions
- Black Friday Sales Disappoint Investors; Amazon Up
- Governments Must Take Steps To Avoid More Dubais: El-Erian
- Goldman Sachs Party Ban: No Gatherings of 12 or More
- Blue Nile CEO: 'We're Having the Best Cyber Monday Ever'
- Nov. 30: Unusual Volume Leaders
- Get Paid Six Figures to Wear a T-Shirt?
- Oil Demand Sees Year-Over-Year Rise, First Since 2007
- BofA Aims to Clearly Spell Out Credit Card Terms
- Should Homeowners Be Able To Walk Away From Mortgage?
Text Size 
Amgen [AMGN
Loading...
()
] reported on Thursday that its fourth-quarter profit edged higher, on a reversal of declining sales of its anemia drugs that have been hit with safety concerns and new restrictions on their use and insurance reimbursements.
U.S. sales of the anemia drugs beat analyst estimates for the quarter: Aranesp sold $462 million, compared to projected $398 million; and Epogen sold $638 million, compared to $597 million.
The company also said its closely watched experimental osteoporosis drug denosumab met all goals of a key clinical study, comparing it to a widely used treatment.
The world's biggest biotechnology company by sales posted a quarterly net profit of $835 million, or 76 cents per share, compared with a profit of $833 million, or 71 cents per share, a year ago.
Excluding items, Amgen earned $1 per share. Analysts on average expected 97 cents per share, according to Reuters Estimates.
Amgen shares had lost about a third of their value since the beginning of 2007 as a steady drumbeat of negative news involving its anemia franchise took a heavy toll.
Print
Email
- Ever wished your cab driver would stop chatting and just get to where you're going? Well, that moment is closer than ever.
- UPS is giving its customers the option to offset its carbon emissions when sending a package.
- Romania's presidential campaign has been rocked by a video that may show the president striking a 10-year-old boy.
- Raising alligators is hard work, and the fickle taste of rich consumers has just made it much harder, says the NY Times.
- A recent issue of ESPN Magazine was one of its top sellers ever, and it only took scantily clad athletes to make it happen.
- The continued real estate boom in China is partially fueled by a generational flood of newlyweds.
Data is a real-time snapshot *Data is delayed at least 15 minutes